




RealRate

# PHARMACEUTICAL 2023

## EYENOVIA INC. Rank 292 of 446





# PHARMACEUTICAL 2023

EYENOVIA INC.  
Rank 292 of 446



The relative strengths and weaknesses of EYENOVIA INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of EYENOVIA INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 27% points. The greatest weakness of EYENOVIA INC. is the variable Net Income, reducing the Economic Capital Ratio by 51% points.

The company's Economic Capital Ratio, given in the ranking table, is 7.3%, being 36% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	27,643
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,512
Liabilities, Non-Current	908
Other Assets	2,099
Other Compr. Net Income	0
Other Expenses	1,380
Other Liabilities	8,382
Other Net Income	280
Other Revenues	0
Property and Equipment	1,295
Research and Development	13,379
Selling, General and Administrative Expense	13,533

Output Variable	Value in 1000 USD
Assets	31,036
Liabilities	13,802
Expenses	28,292
Revenues	0
Stockholders Equity	17,235
Net Income	-28,011
Comprehensive Net Income	-28,011
Economic Capital Ratio	7.3%